Literature DB >> 26725900

Follow-up of patients with chronic hepatitis C and a sustained viral response.

Lawrence Serfaty1,2.   

Abstract

Patients with chronic hepatitis C who achieve a sustained virological response (SVR) after antiviral treatment have improved survival and liver-related morbidity compared to non-SVR patients. However, long-term follow-up studies in SVR patients have shown that the regression of fibrosis varies and the risk of liver-related complications remains, even in the absence of cirrhosis. While patients with cirrhosis are still at risk of hepatocellular carcinoma, comorbidities such as diabetes, obesity or alcohol consumption may play a major role in the outcome of liver disease in SVR patients without cirrhosis. The risk of re-infection is high in patients with a persistent risk of contamination such as IV drug users or men who have sex with men. Thus, in the era of highly efficient DAAs regimens, monitoring after a cure of HCV infection remains a major challenge in SVR patients. This review describes long-term HCV infection and liver-related outcomes in SVR patients, as well as the profile of patients who are still at risk of progression, and monitoring techniques including non-invasive markers for the assessment of fibrosis.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  NAFLD; fibrosis; hepatocellular carcinoma; non-invasive markers

Mesh:

Substances:

Year:  2016        PMID: 26725900     DOI: 10.1111/liv.13016

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  10 in total

1.  Symbiotic chemo- and immuno-therapy for hepatitis B and C viruses.

Authors:  Babita Agrawal; Rakesh Kumar
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

2.  The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial.

Authors:  Rae Jean Proeschold-Bell; Donna M Evon; Christina Makarushka; John B Wong; Santanu K Datta; Jia Yao; Ashwin A Patkar; Paolo Mannelli; Terra Hodge; Susanna Naggie; Julius M Wilder; Michael W Fried; Donna Niedzwiecki; Andrew J Muir
Journal:  Contemp Clin Trials       Date:  2018-07-10       Impact factor: 2.226

3.  Analysis of Plasma Tenascin-C in Post-HCV Cirrhosis: A Prospective Study.

Authors:  Jennifer H Benbow; April D Elam; Krista L Bossi; Danae L Massengill; Elizabeth Brandon-Warner; William E Anderson; Catherine R Culberson; Mark W Russo; Andrew S deLemos; Laura W Schrum
Journal:  Dig Dis Sci       Date:  2018-01-12       Impact factor: 3.199

4.  What is required for achieving hepatitis C virus elimination in Singapore? A modeling study.

Authors:  Antoine Chaillon; Prem Harichander Thurairajah; John Chen Hsiang; Natasha K Martin
Journal:  J Gastroenterol Hepatol       Date:  2020-09-03       Impact factor: 4.029

5.  CXCL9-11 polymorphisms are associated with liver fibrosis in patients with chronic hepatitis C: a cross-sectional study.

Authors:  María Ángeles Jiménez-Sousa; Ana Zaida Gómez-Moreno; Daniel Pineda-Tenor; Luz Maria Medrano; Juan José Sánchez-Ruano; Amanda Fernández-Rodríguez; Tomas Artaza-Varasa; José Saura-Montalban; Sonia Vázquez-Morón; Pablo Ryan; Salvador Resino
Journal:  Clin Transl Med       Date:  2017-07-28

6.  Impaired Platelet Aggregation and Rebalanced Hemostasis in Patients with Chronic Hepatitis C Virus Infection.

Authors:  Nick S Nielsen; Sofie Jespersen; Julie C Gaardbo; Caroline J Arnbjerg; Mette R Clausen; Mette Kjær; Jan Gerstoft; Vibe Ballegaard; Sisse R Ostrowski; Susanne D Nielsen
Journal:  Int J Mol Sci       Date:  2017-05-08       Impact factor: 5.923

7.  Significance of UGT1A1*28 Genotype in Patients with Advanced Liver Injury Caused By Chronic Hepatitis C.

Authors:  Jelena Jordovic; Ksenija Bojovic; Jasmina Simonovic-Babic; Vladimir Gasic; Nikola Kotur; Branka Zukic; Marija Vukovic; Sonja Pavlovic; Ivana Lazarevic; Ivana Bekic; Natasa Nikolic; Aleksandar Uroševic; Nikola Mitrovic; Dragan Delic
Journal:  J Med Biochem       Date:  2019-03-01       Impact factor: 3.402

8.  Assessment of Liver Stiffness Regression and Hepatocellular Carcinoma Risk in Chronic Hepatitis C Patients after Treatment with Direct-Acting Antiviral Drugs.

Authors:  Martynas Ridziauskas; Birutė Zablockienė; Ligita Jančorienė; Artūras Samuilis; Rolandas Zablockis; Aušrinė Jackevičiūtė
Journal:  Medicina (Kaunas)       Date:  2021-02-26       Impact factor: 2.430

Review 9.  Hepatitis C virus: A critical approach to who really needs treatment.

Authors:  Elias Kouroumalis; Argyro Voumvouraki
Journal:  World J Hepatol       Date:  2022-01-27

10.  Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study.

Authors:  Ana Zaida Gomez-Moreno; Daniel Pineda-Tenor; Maria Angeles Jimenez-Sousa; Juan Jose Sánchez-Ruano; Tomas Artaza-Varasa; Jose Saura-Montalban; Pablo Ryan; Salvador Resino
Journal:  PLoS One       Date:  2017-09-07       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.